Skip to main content
Equibles
JANX logo

JANX · Janux Therapeutics, Inc. · Metrics

Track JANX — free

Use JANX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research JANX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$17.20 +0.46 (+2.75%) At close · Oct 20
Russell 2000 member Rebalance outlook locked
Market Cap
$1.02B
Shares
61.14M
Volume · Oct 20 869.47K Avg daily vol (3M) 845.94K

JANX metrics

81 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$17.20
Market cap
$1.02B

Price action

20 metrics
Price change (1W)
-7.8%
Price change (30D)
-1.6%
Price change (3M)
+4.3%
Price change (6M)
+5.5%
Price change (YTD)
+21.3%
Price change (1Y)
-37.4%
Trailing year
Price change (5Y)
-22.2%
52-week high
$34.74
52-week low
$12.18
Change from 52-week high
-51.8%
Change from 52-week low
+37.4%
Annualized volatility
73.0%
Annualized volatility (3M)
48.1%
Beta
1.1
RSI (14D)
45.3
Price vs SMA 50
-4.3%
Price vs SMA 200
+10.3%
Avg volume (3M)
844,942
Relative volume
1.1
Average dollar volume
$14.54M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
61.14M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1.6×
reciprocal yield 62.4%
EV / EBITDA
—
EV / EBIT
—
P / sales
42.1×
reciprocal yield 2.4%
P / book
1.1
reciprocal yield 91.9%
FCF yield
-4.2%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-10.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
162.2×
reciprocal yield 0.6%
EV / revenue historical average (5Y)
162.2×
reciprocal yield 0.6%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-12-01

Profitability

9 metrics
Gross margin
—
Operating margin
-598.1%
Trailing 12 months
Net margin
-427.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$143.56M
Net income (TTM)
−$102.59M
Trailing 12 months
Diluted EPS (TTM)
$-1.64
FCF margin
-174.7%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.38
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-2.30
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.64
Operating cash flow per diluted share (TTM)
$-0.67
Free cash flow per diluted share (TTM)
$-0.68
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$1.99
Stock compensation per diluted share (TTM)
$0.59
Book value per share
$15.85

Growth

11 metrics
Revenue growth YoY
-5.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$24.00M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.7%
Year over year · more shares
Revenue CAGR (3Y)
+5.1%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-11.1%
Return on assets
-10.2%
Debt / equity
0.0
Current ratio
16.3
EBITDA (TTM)
—
Free cash flow (TTM)
−$41.92M
Quick ratio
16.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$970.91M
Latest balance sheet
Cash & equivalents
$27.77M
Total assets
$1.01B
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$41.25M
Capital expenditures (TTM)
$674,000
R&D (TTM)
$123.98M
SG&A (TTM)
—
Stock compensation (TTM)
$36.89M
R&D / revenue
516.6%
Stock compensation / revenue
153.7%

Ownership (13F)

9 metrics
13F filers
199
13F filer change QoQ
+7
Institutional ownership
100.2%
Conviction holders (share of 13F filers)
0.5%
Crowding (high-turnover and private-fund holders)
52.4%
Private-fund adviser ownership
41.6%
Active holders' share change QoQ
-1.4%
Holder tenure
11.8
Price vs estimated holder cost
-30.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
13.7%

Short interest

3 metrics
Short interest
9.3%
Latest settlement · 5.9 days to cover
Days to cover
5.9d
Short-squeeze score
73 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1817713 CUSIP 47103J105 13F (30d) 15 filings 15 filers Visit website Investor relations